Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2026
UroGen lowers 2026 JELMYTO revenue guidance
UroGen updated its full-year 2026 net product revenue guidance for JELMYTO to approximately $90 million, down from its prior range of $97 million to $101 million.
2026
UroGen reports third-quarter 2026 financial results
UroGen Pharma Ltd. announced its third-quarter 2026 financial results, reporting total revenue of $89.0 million and a net loss of $1.5 million.
2020
FDA approves Jelmyto for low-grade upper tract urothelial cancer
The FDA approved mitomycin gel, marketed as Jelmyto by UroGen Pharma, for the treatment of low-grade upper tract urothelial cancer.